- Home
- APLT vs FORA Comparison
APLT vs FORA Comparison
Compare APLT & FORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- FORA
- Stock Information
- Founded
- APLT 2016
- FORA 2014
- Country
- APLT United States
- FORA United States
- Employees
- APLT N/A
- FORA 37
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- FORA Computer Software: Prepackaged Software
- Sector
- APLT Health Care
- FORA Technology
- Exchange
- APLT Nasdaq
- FORA Nasdaq
- Market Cap
- APLT 63.6M
- FORA 69.4M
- IPO Year
- APLT 2019
- FORA N/A
- Fundamental
- Price
- APLT $0.41
- FORA $2.27
- Analyst Decision
- APLT Buy
- FORA Strong Buy
- Analyst Count
- APLT 6
- FORA 1
- Target Price
- APLT $6.10
- FORA $5.00
- AVG Volume (30 Days)
- APLT 771.9K
- FORA 75.0K
- Earning Date
- APLT 11-06-2025
- FORA 11-12-2025
- Dividend Yield
- APLT N/A
- FORA N/A
- EPS Growth
- APLT N/A
- FORA N/A
- EPS
- APLT N/A
- FORA N/A
- Revenue
- APLT $121,000.00
- FORA $25,031,040.00
- Revenue This Year
- APLT N/A
- FORA $47.82
- Revenue Next Year
- APLT $5,931.24
- FORA $10.11
- P/E Ratio
- APLT N/A
- FORA N/A
- Revenue Growth
- APLT N/A
- FORA 18.59
- 52 Week Low
- APLT $0.30
- FORA $1.64
- 52 Week High
- APLT $10.62
- FORA $4.03
- Technical
- Relative Strength Index (RSI)
- APLT 38.50
- FORA 60.82
- Support Level
- APLT $0.40
- FORA $2.20
- Resistance Level
- APLT $0.46
- FORA $2.39
- Average True Range (ATR)
- APLT 0.03
- FORA 0.13
- MACD
- APLT -0.01
- FORA 0.02
- Stochastic Oscillator
- APLT 7.74
- FORA 76.47
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.